【摘要】： ErbB2是具有酪氨酸激酶活性的跨膜糖蛋白,屬于表皮生長(zhǎng)因子受體家族,在多種癌細(xì)胞特別乳腺癌中有高表達(dá),針對(duì)其的單克隆抗體具有潛在的治療效果。本實(shí)驗(yàn)室自行研制的抗ErbB2嵌合抗體chA21具有抑制高表達(dá)ErbB2乳腺癌細(xì)胞生長(zhǎng)的作用。本論文從chA21的大規(guī)模純化生產(chǎn)工藝、質(zhì)量研究以及工藝改進(jìn)進(jìn)行了研究: 1、以填充床生物反應(yīng)器大規(guī)模培養(yǎng)CHO工程細(xì)胞株表達(dá)的上清為原料,采用親和層析、凝膠過濾除鹽、陽(yáng)離子交換層析、分子篩等步驟,分離純化嵌合抗體chA21,建立大規(guī)模純化工藝。該工藝能有效解決抗體純化過程形成的多聚體問題,去除內(nèi)毒素和DNA殘留;可以確保每批純化10L～20L培養(yǎng)上清,蛋白總回收率大于50%,純度可達(dá)98%。 2、按照國(guó)家對(duì)生物制品的質(zhì)量要求,對(duì)大規(guī)模生產(chǎn)的chA21原液產(chǎn)品進(jìn)行了全面鑒定和質(zhì)量控制,主要包括含量鑒定、純度和雜質(zhì)污染物的檢測(cè)、理化性質(zhì)鑒定、生物學(xué)活性測(cè)定等。鑒定結(jié)果表明制備的chA21產(chǎn)品符合動(dòng)物實(shí)驗(yàn)和臨床試驗(yàn)的要求。 3、最后進(jìn)一步對(duì)純化工藝新策略摸索,探討可以替代的純化方案。 嵌合抗體大規(guī)模純化工藝的確定和質(zhì)量研究的初步摸索,為今后的藥物申請(qǐng)奠定了基礎(chǔ)。
[Abstract]:ErbB2 is a transmembrane glycoprotein with tyrosine kinase activity, which belongs to epidermal growth factor receptor family and is highly expressed in many cancer cells, especially breast cancer. The anti-ErbB2 chimeric antibody chA21 developed by our laboratory can inhibit the growth of breast cancer cells with high expression of ErbB2. In this paper, the mass purification process, quality research and process improvement of chA21 were studied. 1. The supernatant of CHO engineering cell line was cultured in packed bed bioreactor as raw material, and affinity chromatography was used. Gel filtration desalination, cation exchange chromatography and molecular sieve were used to isolate and purify chimeric antibody chA21, and a large-scale purification process was established. This process can effectively solve the problem of polymer formation in antibody purification process, remove endotoxin and DNA residues, and ensure the supernatant of each batch of purified 10L~20L culture. The total recovery rate of protein is more than 50 and the purity can reach 98.2. According to the quality requirements of biological products, the products of chA21 raw liquid produced on a large scale have been comprehensively identified and their quality control has been carried out, including content identification. Detection of purity and impurity pollutants, identification of physical and chemical properties, determination of biological activity, etc. The results showed that the product of chA21 was in accordance with the requirements of animal experiment and clinical trial. 3. Finally, the new strategy of purification process was explored, and the alternative purification scheme was discussed. The determination of mass purification process of chimeric antibody and preliminary exploration of quality study have laid a foundation for the application of drugs in the future.
【學(xué)位授予單位】：中國(guó)科學(xué)技術(shù)大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2009
【分類號(hào)】：R392

【共引文獻(xiàn)】

相關(guān)期刊論文 前7條

1 夏夢(mèng);Herceptin治療婦科惡性腫瘤的機(jī)制及應(yīng)用前景[J];國(guó)外醫(yī)學(xué).婦產(chǎn)科學(xué)分冊(cè);2000年04期

2 梁偉,王亞芹,劉興君;腫瘤的靶向介入治療[J];中國(guó)介入影像與治療學(xué);2004年01期

3 倪晶,倪翼,張瑞華,王纓,熊思東;HER-2/neu胞外區(qū)的基因工程表達(dá)及其免疫避孕作用[J];生殖與避孕;2004年01期

4 周瀾華;安金剛;李巍;劉玉峰;;抗白念珠菌人鼠嵌合抗體真核表達(dá)載體的構(gòu)建與表達(dá)[J];中國(guó)皮膚性病學(xué)雜志;2008年05期

5 ;與早期胃癌復(fù)發(fā)有關(guān)的臨床病理特性及生物指標(biāo)的分析(英文)[J];Chinese-German Journal of Clinical Oncology;2011年07期

6 白銀 ,王琰 ,周麗君 ,俞莉章;CONSTRUCTION AND EXPRESSION OF A HUMAN-MOUSE CHIMERIC ANTIBODY AGAINST HUMAN BLADDER CANCER[J];Chinese Journal of Cancer Research;2001年04期

7 ;Expression of c-erbB-2 and glutathione S-transferase-pi in hepatocellular carcinoma and its adjacent tissue[J];World Journal of Gastroenterology;2005年28期

相關(guān)博士學(xué)位論文 前3條

1 胡思怡;重組基因工程抗體和蛇毒C型凝集素類似蛋白在畢赤酵母中表達(dá)及結(jié)構(gòu)功能研究[D];中國(guó)科學(xué)技術(shù)大學(xué);2006年

2 張宏武;c-Myc、FAK、Her-2、CCND1及TopoⅡa在乳腺癌中的變化及其與臨床病理指標(biāo)的關(guān)系[D];中國(guó)協(xié)和醫(yī)科大學(xué);2007年

3 羅弋;抗Peroxiredoxin I肺腺癌噬菌體抗體的制備、抑制肺腺癌細(xì)胞增殖研究及其在荷人肺腺癌裸鼠模型中的放免顯像[D];重慶醫(yī)科大學(xué);2010年

，

本文編號(hào)：2176305